US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Veraxa Biotech AG - Ordinary Shares
(NQ:
VRXA
)
1.130
-0.060 (-5.04%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veraxa Biotech AG - Ordinary Shares
< Previous
1
2
Next >
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
July 20, 2026
Via
Investor Brand Network
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
July 20, 2026
Scientific Advice from the German Regulatory Authority supports the biological rationale and proposed development approach for VERAXA's BiTAC-TCE technology and product candidate, providing an initial...
From
Veraxa Biotech AG
Via
GlobeNewswire
Why VERAXA Biotech AG (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D
July 14, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development
July 13, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’
June 11, 2026
Via
Investor Brand Network
NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Carl von Halem Interim Chief Financial Officer
July 13, 2026
Via
Investor Brand Network
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
July 13, 2026
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs)
From
Veraxa Biotech AG
Via
GlobeNewswire
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
July 10, 2026
From
VERAXA Biotech GmbH
Via
GlobeNewswire
VERAXA Biotech AG (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership
July 08, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition
July 06, 2026
Via
Investor Brand Network
BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
July 06, 2026
Via
Investor Brand Network
BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
July 06, 2026
Via
Investor Brand Network
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
July 06, 2026
Novel conditionally active T cell engagers sourced from proprietary BiTAC® platform are at the basis of advanced partnering initiatives and development activities
From
VERAXA Biotech GmbH
Via
GlobeNewswire
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
July 02, 2026
Via
Investor Brand Network
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
July 02, 2026
ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activities
From
VERAXA Biotech GmbH
Via
GlobeNewswire
Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals
July 01, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Xlife Sciences AG (SIX: XLS) Shareholders Approve All Annual Meeting Proposals
June 29, 2026
Via
Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline
June 24, 2026
Via
Investor Brand Network
BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline
June 24, 2026
Via
Investor Brand Network
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
June 24, 2026
Greater than 60% increase in laboratory space will strengthen R&D capabilities, facilitate acceleration toward clinical development, and increase ability to tap into Heidelberg’s world-class medical...
From
VERAXA Biotech GmbH
Via
GlobeNewswire
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
June 22, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
June 22, 2026
Via
Investor Brand Network
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Reports Proof-of-Concept Data for BiTAC-ADC Cancer Therapy Platform
June 18, 2026
Via
Investor Brand Network
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
June 18, 2026
BiTAC-ADC in vitro data, along with initial data from the most advanced BiTAC-TCE program recently presented at the American Association for Cancer Research (AACR) Annual Meeting, underpin the...
From
VERAXA Biotech GmbH
Via
GlobeNewswire
InvestorNewsBreaks – Why VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’
June 16, 2026
Via
Investor Brand Network
BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Completes Business Combination and Begins Trading on Nasdaq
June 11, 2026
Via
Investor Brand Network
< Previous
1
2
Next >
